| Autor: |
Barnes, Robyn A., Flack, Jeff R., Wong, Tang, Ross, Glynis P., Griffiths, Michelle M., Stephens, Megan, Kourloufas, Laura, Smart, Carmel E., Collins, Clare E., MacDonald‐Wicks, Lesley |
| Předmět: |
|
| Zdroj: |
Diabetic Medicine; Jan2022, Vol. 39 Issue 1, p1-11, 11p |
| Abstrakt: |
Aims: To assess the impact of achieving an Institute of Medicine based personalised weight target in addition to conventional glycaemic management after gestational diabetes mellitus diagnosis on maternal and neonatal outcomes. Methods: A retrospective audit of clinical data (2016–2019) for singleton gestational diabetes pregnancies was conducted in a multi‐ethnic cohort. Logistic regression analyses assessed relationships between achieving, exceeding and gaining less than a personalised weight target provided after gestational diabetes diagnosis and rates of large for gestational age, small for gestational age infants, insulin therapy initiation and neonatal outcomes. Adjusted odds ratios (aOR) were adjusted for glucose 2‐h post‐glucose load value, family history of type 2 diabetes, previous gestational diabetes, macrosomia in a previous pregnancy, and East and South‐East Asian ethnicity. Results: Of 1034 women, 44% (n = 449) achieved their personalised weight target. Women who exceeded their personalised weight target had significantly and higher mean insulin doses (28.8 ± 21.5 units vs. 22.7 ± 18.7, p = 0.006) and higher rates of large for gestational age infants (19% vs. 9.8%, p < 0.001), with aOR of 1.99 [95% CI 1.25–3.15] p = 0.004, but no difference in rates of small for gestational age infants (5.3% vs. 8.0%) (aOR 0.77 [0.41–1.44] p = 0.41). Lower rates of large for gestational age infants occurred in those who gained below their personalised weight target (aOR 0.48 [0.25–0.95] p = 0.034), but rates of small for gestational age infants concurrently increased (aOR 1.9 [1.19–3.12] p = 0.008). Conclusions: Weight management after gestational diabetes diagnosis does not appear to be too late to confer additional benefits to glucose‐lowering treatment, resulting in lower mean insulin doses, and lower rates of large for gestational age infants without increasing the risk of small for gestational age infants. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text